In order to approve the drug for sale, the FDA will need to impose restrictions to protect public safety.
The regulatory body found the drug met safety and efficacy targets, but a majority of members worried the drug, a hydrocodone bitartrate, would become a “drug of choice” for prescription pain killer addicts.
Bob Rappaport, MD, director of the FDA’s division of anesthesia, analgesia and addiction products tasked the regulators with deciding whether the decision was based on a marked difference between Zohydro and other similarly opioid-based drugs.
More Articles on Anesthesia:
Southern Medical Association Names Anesthesiologist President
Locale Anesthesia Conversion Factors Released From CMS
CareFusion Release Anesthesia Systems With More Patient Protections
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
